A Comparative Analysis of US and UK Site Self-Assessment of Practices in Recruiting and Meeting

2 the Needs of Diverse Patient Populations in Clinical Trials

- 4 Peter Phiri^{1,2}, Diana Foster³, Bupendra Shah³, Sana Sajid¹, Lynis Lewis⁴, Shanaya Rathod¹, Gayathri
- 5 Delanerolle⁵, Jian Qing Shi⁶
- 8 Affiliations

1

3

6 7

16

- 9 ¹Southern Health NHS Foundation Trust, Clinical Trials Facility, Tom Rudd Unit, Moorgreen Hospital,
- 10 Southampton, SO30 3JB, UK
- ²School of Psychology, University of Southampton, University Road, Southampton, SO17 1BJ, UK
- ³Society of Clinical Research Sites, 7250 Parkway Drive, Suite 405, Hanover, MD 21076, USA
- ⁴Service Director R&D, Central and North-West London NHS Foundation Trust, London, NW1 3AX, UK
- ⁵Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK
- 15 ⁶Southern University of Science and Technology, Shenzhen, 518055, China
- 17 Corresponding Author:
- 18 Dr Peter Phiri, Director of Research & Innovation,
- 19 Southern Health NHS Foundation Trust,
- 20 Southampton, SO30 3JB, UK
- 21 peter.phiri@southernhealth.nhs.uk

23 **ABSTRACT** 24 **Background** 25 The comparative analysis of site practices in recruiting and outreach of diverse patient populations in 26 clinical trials is needed for a harmonious approach to navigating solutions for improving patient diversity 27 globally. With the availability of the Diverse Site Assessment Tool (DSAT), such analyses have become 28 feasible. 29 30 Methods 31 This study presents a comparison of self-reported data related to diversity best practices using the DSAT 32 by members of clinical trials research sites from three distinct cohorts in the United States (US) and 33 United Kingdom (UK). The Diverse Site Assessment Tool (DSAT) is a 25-item self-report measure, 34 exploring best practices for the recruitment of diverse patient populations during clinical trials. The DSAT 35 was administered online via the Qualtrics XM platform. DSAT data for each of these cohorts were 36 retrieved and scored and individual item means were used to conduct reliability, descriptive and 37 inferential statistical analysis. 38 39 **Findings** 40 Results indicate that the DSAT is an exceptionally reliable instrument for self-assessment of diversity best 41 practices. Results also showed that among the three DSAT sections, the section of patient focused services 42 shows the lowest scores regardless of the cohort and that DSAT section scores were considerably different 43 between the 2 US cohorts as well as between the US and UK cohorts. Overall, DSAT scores were higher 44 for US cohorts than for the UK cohort. 45 46 **Interpretation** 47 Different stakeholders from the US and UK might want to examine the findings of this study carefully 48 and discuss its implications for their own country, sites within it and discuss how harmonized efforts for 49 diversity in clinical trials can be established. 50 51 **Funding** 52 Funded by the The Society of Clinical Research Sites, USA. 53

Background:

Research on clinical trials has well established that the demographics of participants in clinical trials are not necessarily reflective of the actual population who will be the end users of the outcome product following decades of intensive research. Regulatory agencies such as the Food and Drug Administration has a long-documented history of trying to expand the nature of participants in clinical trials¹. Yet, challenges related to diversity of participants in clinical trials remain and with efforts towards harmonisation, regulatory agencies such as the Food and Drug Administration (FDA), health systems agencies such as the National Health Service have further stepped up to address the inequities of representation. Frameworks, guidance, incentives, white papers, programs, and materials²⁻¹⁴ have either been developed or are being developed to help improve diversity of participants in clinical trials.

One of the positive forces towards diversity in clinical trials and a notable resource is the Diversity Site Assessment Tool (DSAT) developed by Dr. Foster and partners associated with the Diversity Awareness Program at the Society for Clinical Research Sites, an organisation representative of the needs of clinical research sites globally ^{15,16}. The DSAT is a 25-item self-assessment tool based on identifying best practices related to recruitment of diverse patient populations during clinical trials and is considered to be an industry gold standard that can be completed by members of a clinical trial site to identify the capacity of their site for recruiting and meeting the needs of diverse patients in clinical trials conducted by their site. The 25 items are divided into three sections: a 10-item Site Overview section, a 9item Site Recruitment and Outreach section and a 6-item Patient Focused Services section. Each of these sections are scored on a 6-point scale (1-Hardly ever; 6-Always), allowing site members to gain an comprehensive self-evaluation of the extent to which they are engaged in best practices associated with diversity in clinical trials. The scoring mechanism of the DSAT also provides an opportunity for a comparative analysis among and across sites, locally as well as globally. Given established reliability and validity of the DSAT, it has been argued that it provides the global clinical trials industry a tremendous opportunity to use a continuous quality improvement and systems-based approach to address recruitment of diverse populations in clinical trials¹⁵⁻¹⁷. Since its inception, the DSAT has been discussed at numerous forums for widespread adoption so that the clinical trials industry can benefit from its findings and tailored resources can be directed to help improve diversity in clinical trials.

Research using DSAT is at a nascent stage as only some analysis of data from US clinical trials site has been published. More robust studies especially those that provide insights into the current practices at clinical sites in other countries and their needs pertaining to improving diversity of participants in the clinical trials are much needed. With increased globalization of pharmaceutical product development and testing and the needs associated with harmonization, studies comparing clinical trial site's best practices in diversity recruitment become necessary and important for a global dialogue and

89

90

919293

94

95

96

97

98

99

100

101

102

103

104

105

106107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

effort towards improving diversity in clinical trials. This study aims to address this gap in the literature by comparing DSAT data completed by members of clinical trials research sites from three cohorts, two from United States and one from United Kingdom. Methods **Study Design** A cross-sectional observational study was delivered digitally. Quantitative data was collected through an online survey questionnaire using the Qualtrics Core XM platform to better understand the understand knowledge, expertise, and best practices to meet the needs of the diverse population in the UK. This study is based on a retrospective cohort analysis of DSAT data completed by three cohorts of clinical trials site members: two from the USA and one from the UK. The survey link for DSAT was distributed over a 1year period to research active sites. US cohort 1 were provided access to the DSAT starting April 2021; US cohort 2 were provided access starting March 2021; UK cohort were provided access starting September 2022. Data was extracted in March 2023 for each of the cohorts, results were deidentified and imported to MS Excel to allow for comparison of DSAT section scores and individual item means. JASP, an open-source statistics program, was utilized to conduct reliability, descriptive and inferential statistical analysis¹⁸. **Materials** The survey consisted of a section collecting background information about the participant and their site, followed by the Diversity Site Assessment Tool (DSAT). The DSAT is a 25-item self-report measure consisting of three sections which are indicators of best practices for the recruitment of diverse patient populations during clinical trials: Site Overview, Site Recruitment and Outreach, and Patient Focused Services. Each of the total 25 items on DSAT would require a site representative participant to self-report on each item on a 6-point scale. Each item from the DSAT is scored based on 1 point for answering "Hardly ever (<or = 5% of the time)", 2 points for answering "Rarely (6-24% of the time), 3 points for answering "Sometimes (25-49% of the time), 4 points for "Often (50-74% of the time), 5 points for "Nearly Always (75-94% of the time) and 6 point for answering "Always (95% or more of the time)" to each of the diversity best practice specific questions. The total DSAT scale scores have potential to range from 0-150 with higher scores indicating greater use of diversity best practices. The questionnaire was administered and completed online using Qualtrics XM platform in the following format: SECTION 1: Representative participant and site demographic information. SECTION 2: Site Overview (10- items) SECTION 3: Site Recruitment and Outreach (9-items)

123

124

125

126127

128

129

130

131

132

133134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

SECTION 4: Patient Focused Services (6-items) The survey took approximately 15 minutes to complete with participants able to omit questions they did not wish to complete. **Participants** Participants for the first US cohort consisted of members from the non-profit, global representative of clinical sites. Participants for the second US cohort consisted of members associated with an independent, full service clinical trials diversity organization. Participants for the cohort from the United Kingdom were members of NHS and non-NHS sites throughout UK who were approached through multifaceted social media platforms, NIHR networks and other research networks and registers. Results Data for a total of 853 participants was received, with a significantly larger participation from the USA. A total of 224 participants took part in the study. Table 1a and 1b outline the demographic characteristics of the UK and US samples, respectively. Data from all participants was used for the descriptive analysis presented in Table 3. Since some participants did not complete all items across all sections, care was taken during the categorical and comparative analysis to use data for only those participants who had effectively completed most items across all sections to make comparisons meaningful. For comparative analysis, this resulted in an effective response from 703 participants: US Cohort 1 (N=229), US Cohort 2 (N=293) and UK Cohort (N=181). Table 2 presents the results of the reliability analysis. This shows the Cronbach's alpha and the average interitem correlations for all participants and cohorts from both US and UK indicate that the DSAT and items within its three sections have high reliability. Table 3 and Figure 1 provide a descriptive insight into the overall DSAT score and Section scores when all participants were included in the analysis. Based on the mean scores, it can be inferred that on an average, members report that their sites often engaged in activities associated with site overview and site recruitment and outreach best practices, but relatively less frequent (sometimes) in activities associated with patient focused services. Unsurprisingly, the categorical distribution showcased in Figure 1 indicates that 82% members reported always or nearly always experiencing site overview best practices, 70% members reported always or nearly always experiencing site recruitment and outreach best practices but only 59% members reported always or nearly always experiencing patient focused services best practices. Items in the Patient Focused Services section such as "When needed, site has provisions for providing a place to stay for patients and their family members including children" and "Site offers phone prompt for

most frequently used languages (i.e., press 1 for Spanish)" had the lowest mean scores across all three sections.

In Table 4, a comparison of the mean scores for the combined US cohorts with the UK cohorts and the p-values associated with each item on the DSAT is provided. As can be seen, US sites average scores on all 3 sections were closer to 5 (nearly always) whereas UK sites average scores were closer to 4 (often). The mean scores of US sites were significantly higher than UK sites on 23 items and only 2 items (item 8 in Site Overview and item 3 Patient Focused Services) showed no significant difference in means between US and UK cohorts. Three items from the Patient Focused Services section (item 1, item 5 and item 5) and two items from the Site Recruitment and Outreach (item 3 and 5) show the highest difference between US and UK sites. Figures 2a and 2b provide a graphical illustration of the categorical distribution of DSAT sections and total DSAT scores. It is interesting to note that there is at least a 20% difference in percentage of members who indicated nearly always/always in all 3 sections and the total DSAT, with the highest difference between the US and UK cohorts being on the Patient Focused Services section.

(88% US vs 65% UK on Site Overview; 78% US vs 48% UK on Site Recruitment and Outreach; 71% US vs 26% for UK on Patient Focused Services; 83% US vs 54% UK on overall DSAT).

To further delve into the differences between the US and UK cohort responses, mean scores of the UK cohort was compared with segregated data from each of the US cohorts (US cohort 1 and US cohort 2). Table 5, Figure 3a, Figure 3b and the previously presented Figure 2b provide these comparisons. When mean scores of the three cohorts are examined, it becomes clear that the mean scores for US cohort 2 are significantly higher than those compared to mean scores for US cohort 1 and the UK cohort. It is also interesting to note that mean scores for the US 1 cohort were lower than the UK cohort for only 8 out of 25 items (7 items in the Site Overview section and 1 item from the Patient Focused Services section). Overall, the highest difference between US cohort 2 and the UK cohort means were on 3 items in the Patient Focused Services section (items 1,5, and 6) and two items in the Site Recruitment and Outreach section items (items 3 and 6). Overall highest difference between US cohort 1 and US cohort 2 were on 1 item in the Site Overview section (item 6) and 3 items in the Site Recruitment and Outreach section (items 3, 6, and 7). The graphics from Figure 3a, 3b and 2 b clearly indicate the percentage of members from US cohort 2 who indicated nearly always/always in all 3 sections and the total DSAT was significantly higher than US cohort 1 and the UK cohort, wherein the UK cohort had the lowest percentage (80% US 1, 94% US 2 vs 65% UK on Site Overview; 63% US 1, 89% US 2 vs 48% UK on Site Recruitment and Outreach; 57% US 1, 80% US 2 vs 26% for UK on Patient Focused Services; 69% US 1, 94% US 2 vs 54% UK on total DSAT).

Discussion

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

Globally, there is a movement underway to improve diversity of populations participating in clinical trials. Governmental and regulatory agencies, non-profits and private enterprises involved in discovery, development and approval of pharmaceutical products are clearly expending efforts towards greater representation of diverse ethnic populations and groups that are usually underrepresented in clinical trials. In such an environment, the availability of a self-assessment instrument such as the DSAT has been identified as providing an opportunity to utilize a continuous quality improvement and collaborative approach to diversity recruitment, outreach, and management in clinical trials. As prior published studies using the DSAT primarily showcased perspectives of site members from the United States, there was a need to examine the utility of DSAT in other countries and provide comparative data on the status of practices related to diversity recruitment, outreach, and management in clinical trials. This study is a step towards addressing the gap.

There are several noteworthy findings from this study which would be an excellent utility to the clinical trials industry and those involved in partnering with it. First, the reliability of the DSAT was consistently high across all 3 cohorts that utilized it. This finding is important because it showcases the fact that the instrument can be used in non-US contexts for the self-assessment of best practices involved in clinical trials industry as it pertains to diversity recruitment, outreach and management. Second, the descriptive findings of the study clearly indicate that practices associated with patient focused services such as phone prompts for language services, providing access to a place for patient's families and children to stay are areas that can be improved upon. The findings also indicate that outreach and recruitment activities are sites are still not optimally conducting outreach to minority-based organisations to establish a network of referrals and using appropriate media outlets as well as creating target population specific retention plans. These findings indicate that clinical trial sponsors and sites may need some assistance and training in these areas of best practices. It was both interesting and heartening to note that the highest mean score was associated with the item "Site management team supports the recruitment of diverse patients", which indicates that a culture of diversity recruitment, outreach and management is prevalent in the industry. The third and an important finding from this study was that the DSAT scores (all three sections and total) for the US cohort was significantly higher than the UK cohort. While not investigated in this study, a potential reason for this finding could be related to the history of how the FDA, the industry, and its stakeholders such as SCRS have engaged in activities that may have spurred the early adoption of best practices in improving diversity in clinical trials. Alternatively, another reason could be that the norms associated with clinical trials recruitment, outreach, and management as measured in the DSAT were shaped in the US and are now slowly being adopted in the UK. Different stakeholders from US and UK might want to examine the findings carefully and discuss its implications for their own country and sites within it.

Finally, it was interesting to note the difference in the DSAT scores between the two US cohorts. Future case studies may want to explore and investigate how best practices in diversity are being integrated in different countries and in different states within a regionally large and diverse country such as the US. There are several limitations that should be considered when taking these findings into consideration. This study was based on a secondary analysis of data from cohorts of members that were involved in this study. These cohorts participated during different time frame and had access to the DSAT via different mechanisms depending on how they were invited or recruited. Primary research studies using study designs that will provide for simultaneous access and participation are needed. Conclusion

224

225

226

227

228

229

230

231

232 233

234

235

236

237

238

This study provides an important insight to the utility of DSAT for cross-country comparisons. It found that overall, the best practices associated with site management, site recruitment and outreach of diverse populations are nearly always utilized whereas practices associated with patient focused services are sometimes or utilized often. It also found that best practices identified by DSAT are utilized at a higher rate in clinical trials sites in the United States as compared to sites in the United Kingdom.

Table 1a. UK Demographics

Characteristics		Frequency	Proportion (%)
	Man	55	21.0
	Woman	152	58.0
	Transgender	0	0
Gender	Non-binary	1	0.4
	Prefer not to say	3	1.2
	Non-gender	0	0
	Prefer to use another term	3	1.2
	<18	48	18.3
Age	18-25	39	14.9
Age	26-35	62	23.7
	>35	62	23.7
	White – English/ Welsh/ Scottish/ Northern	154	58.8
	Irish/ British		
	White – Irish	4	1.5
	White – Gypsy or Irish Traveller	1	0.4
	Any other white background	11	4.2
	White and Black Caribbean	1	0.4
	White and Black African	1	1.2
	White and Asian	3	1.2
	Any other mixed/multiple ethnic background	4	1.5
	Indian	9	3.4
Ethnicity	Pakistani	5	1.9
Ethnicity	Sri Lankan	0	0
	Bangladeshi	0	0
	Chinese	0	0
	Korean	0	0
	Other Asian Background	3	1.2
	African	6	2.3
	Caribbean	0	0
	Any other Black/Africa/Caribbean	0	0
	background		
	Arab	1	0.4
	Other ethnic group	3	1.2
	Christian	77	29.4
	Jewish	2	0.8
	Muslim	13	5.0
	Catholic	7	2.7
	Hindu	2	0.8
	Buddhist	72	27.5
	Atheist	28	10.7
	Mixed	7	2.7
Educational	No formal educational qualifications	0	0

Qualifications	GCSE, O'Level, standard grade or equivalent	10		3.8	
	A-level, higher grade or equivalent	21		8.0	
	Undergraduate Degree	79		30.2	
	BA		31		11.8
	MBBS		17		6.5
	MB ChB		20		7.6
	BSc		120		45.8
	Foundation Degree		7		2.7
	Postgraduate degree	103		39.3	
	MA		12		4.6
	MSc		68		26.0
	PhD		22		8.4
	MD		4		1.5
	MPhil		6		2.3
	None		78		29.8
	Academic Institution	12		4.6	
	Primary Care Service	50		19.1	
	Secondary Care Service	92		35.1	
	Tertiary Care Service	8		3.1	
What best describes	Palliative Care Service	0		0	
the type of site you	Social Care Service	1		0.4	
work at?	Community Care Service	0		0	
	Charitable Organisation	12		4.6	
	Free standing	6		2.3	
	Other	22		8.4	
	Yes	149		56.9	
	North East and North Cumbria	149	9	3.4	
	North West Coast		4	1.5	
	Yorkshire and Humber		31	11.8	
	Greater Manchester		16	6.1	
	East Midlands		6	2.3	
	West Midlands		2	0.8	
	West of England		1	0.4	
	Thames Valley and South Midlands		17	6.5	
	East of England		11	4.2	
Is your site part of a	Kent, Surrey and Sussex		8	3.1	
network?	Wessex		14	5.3	
	South West Peninsula		9	3.4	
	North Thames		9	3.4	
	South London		1	0.4	
	North West London		2	0.8	
	No		26	9.9	
	UKTM		1	0.4	
	NIHR CRN		116	44.3	
	Unsure		25	9.5	
	Other		21	8.0	
	J				

	Unsure	43	16.4	240
	England	116	44.3	241
In what country is	Wales	0	0	241
your site located?	Scotland	19	7.3	242
	Northern Ireland	0	0	243

Table 1b. USA Demorgaphics

244

245

246247

248

249

		US	Site 1	US	Site 2	Tota	al US
		Frequency	Proportion	Frequency	Proportion	Frequency	Proportion
			(%)		(%)		(%)
	Academic	48	16.6	1	0.4	49	8.6
What best describes	Freestanding Research Center	132	45.5	166	59.7	298	52.5
the type of site you	Hospital	37	12.8	5	1.8	42	7.4
work at?	Physician Practice/Clinic	73	25.2	106	38.2	179	31.5
	Total	290	100	278	100	568	100
	Yes	129	44.2	113	40.9	242	42.6
Is the site part of a	No	135	46.6	163	59.1	298	52.5
network?	Unsure	28	9.6	-	-	28	4.9
	Total	292	100	276	100	568	100
	Assistant	5	1.7	-	-	5	0.9
	Director/ Vice President	51	17.5	-	-	51	9
	Investigator	36	12.3	66	23.7	102	17.9
	Owner/President	24	8.2	-	-	24	4.2
What best describes vour role?	Regulatory/Compliance	8	2.7	-	-	8	1.4
your role:	Research Assistant	-	-	3	1.1	3	0.5
	Site Manager	71	24.3	97	34.9	168	29.5
	Study Co-ordinator	50	17.1	28	10.1	78	13.7
	Other	47	16.1	84	30.2	131	23
	Total	292	100	278	100	570	100
	Less than 10	116	39.7	147	52.9	263	46.1
How many studies is	10-20	69	23.6	85	30.6	154	27.0
your site currently	20-30	34	11.6	30	10.8	64	11.2
conducting?	30+	73	25.0	16	5.8	89	15.6
	Total	292	100	278	100	570	100

Table 2. Reliability Analysis

DSAT Element	UK Cohort			US Cohorts	All				
	α	Average ICC	α	α Average ICC		Average ICC			
Site Overview (10 items)	0.89	0.46	0.90	0.48	0.90	0.48			
Site Recruitment and Outreach (9 items)	0.86	0.40	0.91	0.54	0.91	0.52			
Patient Focused Services (6 items)	0.61	0.23	0.70	0.31	0.72	0.33			
DSAT (25 item)	0.90	0.28	0.94	0.41	0.94	0.40			

DSAT	N	Mean	SD
Section I. Site Overview	852	40.97	21.35
Our site knows the demographic make-up of our community	703	5.24	1.20
Site knows the actual patient demographics of the clinical trial participants	703	5.19	1.34
Investigator, Study Coordinator, and/or support staff are culturally representative of the	702	4.81	1.38
patient population			
Site has staff that can utilize commonly used words in the community for medical	702	5.17	1.35
discussion			
Site staff knows diversity goals	702	5.06	1.47
Site tracks progress toward established diversity goals and knows what marketing or	701	4.35	1.76
outreach strategies works to make them successful			
Site can provide diversity metrics upon request to sponsor at site evaluation	699	4.81	1.66
Site has mechanisms (formal or informal) to make staff culturally aware and sensitive to	699	4.95	1.49
the patient population			
Site management team supports the recruitment of diverse patients	701	5.44	1.27
Site has a process to identify and address barriers	701	4.76	1.59
Section II. Site Recruitment and Outreach	851	33.71	19.93
Site has an established tailored strategy to approach targeted populations for clinical trials	682	4.83	1.56
When needed, site partners with sponsor to create study-specific and target patient	682	4.62	1.73
population specific recruitment plans			
Site creates target patient population specific retention plans	681	4.40	1.87
When needed, site requests appropriately tailored patient materials from sponsor	681	5.03	1.57
Site routinely requests materials (e.g., ICF, patient recruitment materials, patient outcomes	680	4.85	1.73
assessments, E-diaries) in languages predominantly used by members of their patient			
population			
When needed, site conducts outreach to minority-based organizations to establish a	680	4.16	1.90
network of referrals (e.g., churches, community centers, food banks, medical community,			
patient advocacy and support groups, etc.)			
When needed, site utilizes appropriate media outlets (radio, TV, social media) specific to	680	4.40	1.86
the targeted population			
Site uses recruitment materials that have worked in the past to decide upon future strategy	679	4.69	1.73
for recruiting diverse patients			
Site has a mechanism to notify patients for eligibility in clinical trials	680	5.18	1.45
Section III. Patient Focused Services	849	20.63	12.59
Informed Consent form is available, pre-translated and pre-IRB approved in relevant	675	4.73	1.79
languages			
If allowed by state/local regulations, site accommodates working patients by offering	673	4.70	1.62
hours of operation outside of normal business hours (i.e., early arrivals and/or after hours			
appointments) and weekend visits			
Site offers phone prompt for most frequently used languages (i.e., press 1 for Spanish)	674	3.50	2.56
Site provides transportation services or requests reimbursement from sponsor as needed	674	4.90	1.59
When needed, site has provisions for providing a place to stay for patients and their family	674	3.33	2.31
members including children			
Stipends are offered and/or distributed in a timely manner and method easy for patient use	673	4.88	1.75

Table 4. Comparison of DSAT Scores of US (N=522) and UK (N=181) Study Participants

DSAT	US Mean	UK Mean	Sig.
Section I. Site Overview	44.06	33.46	< 0.00
Our site knows the demographic make-up of our community	5.30	5.06	0.01
Site knows the actual patient demographics of the clinical trial participants	5.37	4.67	< 0.00
Investigator, Study Coordinator, and/or support staff are culturally	4.92	4.49	< 0.00
representative of the patient population			
Site has staff that can utilize commonly used words in the community for	5.35	4.65	< 0.00
medical discussion			
Site staff knows diversity goals	5.13	4.84	0.02
Site tracks progress toward established diversity goals and knows what	4.50	3.92	< 0.00
marketing or outreach strategies works to make them successful			
Site can provide diversity metrics upon request to sponsor at site evaluation	5.09	3.98	< 0.00
Site has mechanisms (formal or informal) to make staff culturally aware and	4.97	4.89	0.54
sensitive to the patient population			
Site management team supports the recruitment of diverse patients	5.50	5.28	0.04
Site has a process to identify and address barriers	4.85	4.48	0.00
Section II. Site Recruitment and Outreach	37.44	24.58	< 0.00
Site has an established tailored strategy to approach targeted populations for	4.97	4.41	< 0.00
clinical trials			
When needed, site partners with sponsor to create study-specific and target	4.85	3.97	< 0.00
patient population specific recruitment plans			
Site creates target patient population specific retention plans	4.74	3.40	< 0.00
When needed, site requests appropriately tailored patient materials from	5.20	4.50	< 0.00
sponsor			
Site routinely requests materials (e.g., ICF, patient recruitment materials,	5.17	3.91	< 0.00
patient outcomes assessments, E-diaries) in languages predominantly used by			
members of their patient population			
When needed, site conducts outreach to minority-based organizations to	4.44	3.31	< 0.00
establish a network of referrals (e.g., churches, community centers, food banks,			
medical community, patient advocacy and support groups, etc.)			
When needed, site utilizes appropriate media outlets (radio, TV, social media)	4.66	3.62	< 0.00
specific to the targeted population			
Site uses recruitment materials that have worked in the past to decide upon	4.87	3.82	< 0.00
future strategy for recruiting diverse patients			
Site has a mechanism to notify patients for eligibility in clinical trials	5.34	4.68	< 0.00
Section III. Patient Focused Services	23.55	13.51	< 0.00
Informed Consent form is available, pre-translated and pre-IRB approved in	5.28	3.10	< 0.00
relevant languages			
If allowed by state/local regulations, site accommodates working patients by	4.92	4.04	< 0.00
offering hours of operation outside of normal business hours (i.e., early arrivals			
and/or after hours appointments) and weekend visits			
Site offers phone prompt for most frequently used languages (i.e., press 1 for	3.41	3.76	0.13
Spanish)			
Site provides transportation services or requests reimbursement from sponsor as	5.20	4.00	< 0.00
needed			
When needed, site has provisions for providing a place to stay for patients and	3.72	2.18	< 0.00
their family members including children			
Stipends are offered and/or distributed in a timely manner and method easy for	5.56	2.82	< 0.00
patient use	1		1

Table 5. Comparison of DSAT Scores By Data Source (US 1 (N=229), US 2 (N=293) and UK (N=181)

Table 5. Comparison of DSAT Scores By Data Source (US 1 (N=229), US 2 (N=293) and UK (N=181)							
DSAT	US1	US 2	UK	Sig			
	Mean	Mean	Mean				
Section I. Site Overview	36.26	51.51	33.46	< 0.001			
Our site knows the demographic make-up of our community	5.01	5.53	5.06	< 0.001			
Site knows the actual patient demographics of the clinical trial participants	5.01	5.66	4.67	< 0.001			
Investigator, Study Coordinator, and/or support staff are culturally	4.59	5.18	4.49	< 0.001			
representative of the patient population							
Site has staff that can utilize commonly used words in the community for	5.04	5.58	4.65	< 0.001			
medical discussion							
Site staff knows diversity goals	4.64	5.51	4.84	< 0.001			
Site tracks progress toward established diversity goals and knows what	3.87	4.99	3.92	< 0.001			
marketing or outreach strategies works to make them successful							
Site can provide diversity metrics upon request to sponsor at site	4.56	5.51	3.98	< 0.001			
evaluation							
Site has mechanisms (formal or informal) to make staff culturally aware	4.44	5.38	4.89	< 0.001			
and sensitive to the patient population							
Site management team supports the recruitment of diverse patients	5.24	5.70	5.28	< 0.001			
Site has a process to identify and address barriers	4.31	5.28	4.48	< 0.001			
Section II. Site Recruitment and Outreach	28.82	45.67	24.58	< 0.001			
Site has an established tailored strategy to approach targeted populations	4.44	5.36	4.41	< 0.001			
for clinical trials							
When needed, site partners with sponsor to create study-specific and target	4.33	5.23	3.97	< 0.001			
patient population specific recruitment plans							
Site creates target patient population specific retention plans	3.99	5.30	3.40	< 0.001			
When needed, site requests appropriately tailored patient materials from	4.73	5.55	4.50	< 0.001			
sponsor							
Site routinely requests materials (e.g., ICF, patient recruitment materials,	4.78	5.46	3.91	< 0.001			
patient outcomes assessments, E-diaries) in languages predominantly used							
by members of their patient population							
When needed, site conducts outreach to minority-based organizations to	3.72	4.98	3.31	< 0.001			
establish a network of referrals (e.g., churches, community centers, food							
banks, medical community, patient advocacy and support groups, etc.)							
When needed, site utilizes appropriate media outlets (radio, TV, social	3.91	5.21	3.62	< 0.001			
media) specific to the targeted population	0.71	0.21	0.02	101001			
Site uses recruitment materials that have worked in the past to decide upon	4.41	5.39	3.82	< 0.001			
future strategy for recruiting diverse patients	1.11	3.37	3.02	\0.001			
Site has a mechanism to notify patients for eligibility in clinical trials	4.88	5.69	4.68	< 0.001			
Section III. Patient Focused Services	18.54	28.33	13.51	< 0.001			
Informed Consent form is available, pre-translated and pre-IRB approved	4.81	5.62	3.10	< 0.001			
in relevant languages	7.01	3.02	3.10	<0.001			
If allowed by state/local regulations, site accommodates working patients	4.59	5.19	4.04	< 0.001			
by offering hours of operation outside of normal business hours (i.e., early	4.39	3.19	4.04	<0.001			
arrivals and/or after hours appointments) and weekend visits							
Site offers phone prompt for most frequently used languages (i.e., press 1	2.90	3.79	3.76	< 0.001			
for Spanish)	2.30	3.13	3.70	<0.001			
Site provides transportation services or requests reimbursement from	4.81	5.48	4.00	< 0.001			
sponsor as needed	4.01	3.40	4.00	<0.001			
When needed, site has provisions for providing a place to stay for patients	3.18	4.12	2.18	< 0.001			
and their family members including children	3.18	4.12	2.18	<0.001			
and then rainity members including children							

Stipends are offered and/or distributed in a timely manner and method	5.21	5.82	2.82	< 0.001
easy for patient use				

Figure 1. DSAT Categorical Scoring Distribution of All Participants

254

255

256257

258 259

260




Figure 2a. DSAT Categorical Scoring Distribution of US Cohorts




Figure 2b. DSAT Categorical Scoring Distribution of UK Cohort




Figure 3a. DSAT Categorical Scoring Distribution of US Cohort 1

262

263 264 265

266 267 268





Figure 3b. DSAT Categorical Scoring Distribution of US Cohort 2



References:

- 1. National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Committee on Women in Science, Engineering, and Medicine; Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research; Bibbins-Domingo K, Helman A, editors. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Washington (DC): National Academies Press (US); 2022 May 17. 3, Policies to Improve Clinical Trial and Research Diversity: History and Future Directions. Available from: https://www.ncbi.nlm.nih.gov/books/NBK584404/. Accessed March 18, 2023.
- 2. US Department of Health and Human Services Office of Disease Prevention and Health Promotion. Healthy People 2030 Framework. Available at: https://health.gov/healthypeople/about/healthy-people-2030-framework. Accessed April 2, 2023.
- 3. Pharmaceutical Research and Manufacturers of America. Pharmaceutical research and manufacturers of America. https://phrma.org/resource-center/Topics/Cost-and-Value/PhRMA-Principles-on-Conduct-of-Clinical-Trials.2020. Accessed on April 2, 2023.
- 4. Guidance, Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations—Eligibility Criteria, Enrollment Practices, and Trial Designs. Accessed on April 2, 2023. Accessed from: https://www.fda.gov/media/127712/download
- 5. <u>US Department of Health and Human Services, National Institute on Minority Health and Health Disparities. Scientific Advancement Plan. Available at: Scientific Advancement Plan (nih.gov).</u> Accessed May 3, 2023.
- 6. U.S. Food and Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; draft guidance for industry 2022. https://www.fda.gov/media/157635/download. Accessed June 1, 2022.
- 7. Hwang TJ, Brawley OW. New Federal Incentives for Diversity in Clinical Trials. N Engl J Med. 2022 Oct 13;387(15):1347-1349. doi: 10.1056/NEJMp2209043. Epub 2022 Oct 8. PMID: 36214598
- 8. National Institute for Health Research. INVOLVE Supporting public involvement in NHS, public health and social research. http://invo.org.uk/
- 9. National Health Service England. Increasing diversity in research participation: A good practice guide for engaging with underrepresented groups. Available from: https://www.england.nhs.uk/aac/publication/increasing-diversity-in-research-participation/. Accessed April 26, 2023.
- 10. Health Research Authority, National Health Service. Increasing the diversity of people taking part in research. Available at: https://www.hra.nhs.uk/planning-and-improving-research/best-practice/increasing-diversity-people-taking-part-research/. Accessed June 2, 2023.
- 11. Farooqi, A., Jutlla, K., Raghavan, R. *et al.* Developing a toolkit for increasing the participation of black, Asian and minority ethnic communities in health and social care research. *BMC Med Res Methodol* **22**, 17 (2022). https://doi.org/10.1186/s12874-021-01489-2
- 12. SCRS Launches Diversity Awareness Program. PRNewswire. 2017. Available at: <u>SCRS Launches Diversity Awareness Program (prnewswire.com)</u>. Accessed: May 3, 2023.
- 13. White Papers. The Society for Clinical Research Sites. Patient Diversity Awareness: Developing a Better Understanding of the Knowledge, Expertise, and Best Practices at Clinical Research Sites to Meet the Needs of an Increasingly Diverse United States Population. Available at: http://myscrs.org/learningcampus/white-papers/. Accessed: May 3, 2023.
- 14. White Papers. The Society for Clinical Research Sites. Recruiting Diverse Patient Populations in Clinical Studies: Factors that Drive Site Success. Available at: http://mvscrs.org/learningcampus/white-papers/. Accessed: May 3, 2023.
- 15. Foster D. A Pilot Study to Examine the Validity and Reliability of a Site Assessment Checklist
 for Evaluation of Best Practices of Recruitment of Diverse Patient Populations for Clinical Trials.
 Insite: The Global Journal for Clinical Research Sites Summer 2020: Page 10-19. Available at:

320 <u>https://cloud.3dissue.com/180561/181052/211361/InSiteS ummer2020/index.html.</u> Accessed: 321 May 31, 2023.

- 16. Foster D. The Diversity Site Assessment Tool (DSAT), Reliability and Validity of the Industry Gold Standard for Establishing Investigator Site Ranking. Integr J Med Sci [Internet]. 2020; 7:13. Available from: https://mbmj.org/index.php/ijms/article/view/266. Accessed: May 31, 2023.
 - 17. Foster D. Identifying Opportunities to Improve Diversity Recruitment. Available at: <u>Identify Opportunities to Improve Diversity Recruitment Total Diversity Clinical Trial Management</u>. Accessed: May 31, 2023.
 - 18. JASP Team (2023). JASP (Version 0.17.2)[Computer software]. <u>Download JASP JASP Free and User-Friendly Statistical Software (jasp-stats.org)</u>